source: Journal of Cardiac Failure

year: 2019

authors: Sharmila Dorbala, Yukio Ando, Sabahat Bokhari, Angela Dispenzieri, Rodney H Falk, Victor A Ferrari, Marianna Fontana, Olivier Gheysens, Julian D Gillmore, Andor W J M Glaudemans, Mazen A Hanna, Bouke P C Hazenberg, Arnt V Kristen, Raymond Y Kwong, Mathew S Maurer, Giampaolo Merlini, Edward J Miller, James C Moon, Venkatesh L Murthy, C Cristina Quarta, Claudio Rapezzi, Frederick L Ruberg, Sanjiv J Shah, Riemer H J A Slart, Hein J Verberne, Jamieson M Bourque

summary/abstract:

Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.

organization: Brigham and Women's Hospital, Harvard Medical School, USA; Kumamoto University, Japan; Columbia University Medical Center/New York Presbyterian Hospital, Columbia University, USA; Mayo Clinic, USA; University of Pennsylvania, USA; University College London, United Kingdom; University Hospitals Leuven, Belgium; University Medical Center Groningen, The Netherlands; Cleveland Clinic, USA; University of Heidelberg, Germany; Foundation Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Italy; University of Pavia, Italy; Yale University School of Medicine, USA; Frankel Cardiovascular Center, USA; Alma Mater-University of Bologna, Italy; Boston Medical Center, USA; Northwestern University, USA; University of Amsterdam, The Netherlands; University of Virginia, USA

DOI: 10.1016/j.cardfail.2019.08.002

read more